We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RayBiotech, Inc. Launches Comprehensive Peptoid-Based Drug Discovery Services
Product News

RayBiotech, Inc. Launches Comprehensive Peptoid-Based Drug Discovery Services

RayBiotech, Inc. Launches Comprehensive Peptoid-Based Drug Discovery Services
Product News

RayBiotech, Inc. Launches Comprehensive Peptoid-Based Drug Discovery Services


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "RayBiotech, Inc. Launches Comprehensive Peptoid-Based Drug Discovery Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Peptoids, a chemically stable class of peptide mimetics, have been recently exploited as ligands to virtually any protein target including antibodies, cellular signaling molecules, or receptors. Aimed at the identification of novel ligands for client-driven drug targets, RayBiotech's new service platform will involve multi-stage screening of targets against a complex combinatorial peptoid library, followed by peptoid sequence refinement and optimization. To enhance the customization of their service, RayBiotech will also offer synthesis of novel peptoid libraries based on the drug target's characteristics, as well as secondary functional assay validation for ligand candidates. This service is intended for select academic labs, pharmaceutical, biopharmaceutical and biotechnology companies and can be applied to virtually any drug target or sample containing desired targets. RayBiotech expects this program to yield high-affinity peptidomimetic diagnostic or drug candidates. The details of the technology, proprietary peptoid libraries and screening methodologies were not disclosed.

RayBiotech's President, COO and Co-founder Rani Huang commented, "The chemical diversity and proteolytic resistance exhibited by peptoids make them ideal drug candidates. Peptoids provide the complexity of a peptide with the stability of a small molecule, and several have already been identified as high-affinity ligands for such optimal drug targets as G protein-coupled receptors. RayBiotech's peptoid discovery services will allow the efficient identification of high-value agonists and antagonists for our clients."

Advertisement